Vlad Coric, Biohaven CEO
Fresh off $11.6B sale to Pfizer, New Biohaven hits Phase III setback just weeks after Vlad Coric chalked up promise
When Pfizer bought up Biohaven’s migraine portfolio in the largest M&A deal of the year earlier this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
